Skip to main content

Approach to ILD in Myositis Syndromes

Jul 28, 2022 3:40 pm

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

They divide myositis-ILD into three main prognostic groups with different treatment approaches:

  1. mild-moderate (subacute),
  2. severe or progressive (acute or subacute) and
  3. rapidly progressive, life-threatening

Treatment options involve immunomodulation in along with the option of antifibrotics. For those with progressive fibrosis they offer a practical guide to assessment, phenotyping according to trajectory and stratified management incorporating multi-disciplinary collaboration between rheumatology and respiratory physicians.

A few key insights from this paper:

  • Identify ILD Risk Factors: data drawn from a meta-analysis of 23 studies, 834 myositis patients:
    • older age at diagnosis
    • arthritis/arthralgia (OR, 3.17)
    • fever (OR, 2.31)
    • elevated ESR
    • elevated CRP (OR, 3.50)
    • ** cancer-associated myositis (OR, 0.36) reduced the risk of developing ILD
    • ** Also, consider consultation with younger patients presenting with ILD, (for an underlying myositis-associated syndrome)
  • Identify 3 main Serologic risk factors for ILD
    • Antisynthetase Antibodies - with antibodies against Jo-1, PL-12, PL-7, EJ, OJ, etc.
    • MDA-5 Antibody -  typical features o fDM rash, characteristic mucocutaneous ulceration and a variable spectrum of ILD, including clinically amyopathic DM (CADM) and RP-ILD 
    •  Anti-PM-Scl antibodies -seen in overlap systemic sclerosis-myositis cases 
  • Poor prognostic factors risk factors -  a recent study suggested these independent risk factors for ILD mortality:
    • age at onset ≥60 years (HR 4.3)
    • CRP ≥10 mg/l (HR 2.6)
    • paO2 saturation <95% (HR 2.0)
    • MDA5 antibody (HR = 7.5)

Treatment approach and options are discussed.

Disclosures
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×